Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

Gerhard Hildebrandt, MD, FACP, and Muhamed Baljevic, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in acute leukemia and multiple myeloma presented during the 2025 ASH Annual Meeting & Exposition.

Brian I. Rini, MD, FASCO, and Katy Beckermann, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in renal cell carcinoma presented during the 2025 ESMO Congress.

Cathy Eng, MD, FACP, FASCO, discusses the clinical significance of a real-world study of KRAS G12C mutations on treatment outcomes in mCRC.

A retrospective study showed immune checkpoint inhibitors may be an option in appropriate indications for patients with neurologic autoimmune disorders.

Alan Tan, MD, discusses how a trial analysis of ipilimumab plus nivolumab in metastatic ccRCC informs strategies for optimal immunotherapy sequencing.

Cathy Eng, MD, FACP, FASCO, discusses real-world data on KRAS G12C–mutated mCRC, highlighting its potential prognostic impact in the frontline setting.

Oncology experts share topline insights from 19 of the most exciting abstracts from the 2025 ASCO Annual Meeting.

Douglas B. Johnson, MD, MSCI, highlighted avenues for improving immunotherapy use in melanoma during Cancer Immunotherapy Awareness Month.

Obrixtamig combined with topotecan demonstrated favorable safety and early efficacy in relapsed/refractory SCLC.

Ryan T. Merrell, MD, discusses current treatment modalities for gliomas in recognition of Brain Tumor Awareness Month.

Ryan Merrell, MD, underscores the need for early glioma detection, advances in IDH-targeted therapy, and emerging immunotherapy in glioblastoma care.

Jill Gilbert, MD, discusses professional strategy techniques that she has found useful through incredibly challenging times.

P-BCMA-ALLO1 displayed high response rates and compelling safety in a heavily pretreated population of patients with relapsed/refractory multiple myeloma.

Carrie L. Kitko, MD, discusses outcomes with axatilimab in patients with chronic graft-vs-host-disease according to prior lines of therapy received.

Step-up dosing with etentamig produced responses and low rates of CRS in relapsed/refractory multiple myeloma.

Networking is an underutilized skill that requires practice but can have a high impact on shaping your career path.

Alan Tan, MD, discusses the IO-based combination therapies that are available for the treatment of patients with RCC.

Drs Dhakal and Baljevic discuss first- and subsequent-line treatment options for patients with multiple myeloma.

Douglas B. Johnson, MD, MSCI, unpacks NCCN guideline updates in melanoma, detailing how neoadjuvant and TIL therapies have been notable advancements.

Alan Tan, MD, discusses the nuances of navigating combination regimens for patients with advanced renal cell carcinoma.

Jill Gilbert, MD, highlights a recent landmark decision by the FDA concerning trial design moving forward for cancer drugs.

Cathy Eng, MD, FACP, FASCO, discusses unmet needs within the metastatic colorectal cancer treatment paradigm.

Brian Rini, MD, and Robert Uzzo, MD, MBA, FACS, highlight the utility of the potential biomarker KIM-1 in renal cell carcinoma.

Brian I. Rini, MD, FASCO, discusses an analysis of clustering from the KEYNOTE-426 study in patients with advanced renal cell carcinoma.

Brian Rini, MD, details recent data in renal cell carcinoma surrounding the utility of KIM-1 as a potential biomarker and next steps for KIM-1 research.

Mary Philip, MD, PhD, discusses research on the key transcriptional and epigenetic programs that regulate CD8 T cell fate decisions in cancer models.

Christine M. Lovly, MD, PhD, discusses the investigation of the EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.

Muhamed Baljevic, MD, FACP, discusses the phase 3 PERSEUS trial in patients with previously untreated multiple myeloma.

Muhamed Baljevic, MD, FACP, discusses the investigation of frontline quadruplet therapies in transplant-ineligible multiple myeloma.

Muhamed Baljevic, MD, FACP, discusses the evolution of quadruplet combination therapies in frontline multiple myeloma.